Inhalation Sciences Sweden AB

Inhalation Sciences Secures Recurring Orders from Global Pharma Customer, Strengthening Preclinical Research Platform

- Inhalation Sciences Sweden AB received two significant orders totaling EUR 55,250 from a recurring global pharmaceutical customer, demonstrating strong validation of their PreciseInhale® research platform. - The orders include both advanced research instruments worth EUR 41,000 and a service agreement worth EUR 14,250, reflecting the company's strategy to build recurring revenue streams. - The European-headquartered pharmaceutical customer, described as a leading player in inhaled pharmaceuticals, has expanded its collaboration through additional service agreements with more underway. - These repeat orders confirm the long-term value and reliability of ISAB's patented preclinical inhalation research technology, which delivers high reproducibility and precision in pharmaceutical development.